IMAGE: Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, to present at the 11th DIA China Annual Meeting 2019 in Beijing, May 20-23 view more
Credit: Insilico
Wednesday, May 15, 2019 – Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at 2019 DIA China Annual Meeting in Beijing on May 23.
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
“We are happy to present our latest research at the 2019 DIA China Annual Meeting, which gathers the leading longevity leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 2019 DIA China Annual Meeting from May 20 – 23 (ICH Day on May 20) is the largest, event in the life sciences industry designed to foster the international exchange of actionable insights to improve health globally through the advancement of lifesaving medicines and technologies in the Asia Pacific region. The event will bring together 2000+ pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe ai@pharma.ai Website: //insilico.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Website: //insilico.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.